- Home
- HOWL
as of 12-10-2025 4:00pm EST
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 64.5M | IPO Year: | 2021 |
| Target Price: | $7.00 | AVG Volume (30 days): | 528.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.59 - $2.38 | Next Earning Date: | 11-04-2025 |
| Revenue: | N/A | Revenue Growth: | -90.55% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered HOWL Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Werewolf Therapeutics Inc. (HOWL)
Director
Avg Cost/Share
$1.01
Shares
44,570
Total Value
$45,015.70
Owned After
2,973,099
SEC Form 4
Director
Avg Cost/Share
$0.99
Shares
34,041
Total Value
$33,700.59
Owned After
2,973,099
SEC Form 4
Director
Avg Cost/Share
$0.97
Shares
16,568
Total Value
$16,070.96
Owned After
2,973,099
SEC Form 4
Director
Avg Cost/Share
$0.97
Shares
53,416
Total Value
$51,813.52
Owned After
2,973,099
SEC Form 4
Avg Cost/Share
$0.97
Shares
83,230
Total Value
$80,733.10
Owned After
4,784,111
SEC Form 4
Other
Avg Cost/Share
$0.97
Shares
83,230
Total Value
$80,733.10
Owned After
4,784,111
SEC Form 4
Director
Avg Cost/Share
$0.87
Shares
36,726
Total Value
$31,951.62
Owned After
2,973,099
SEC Form 4
Avg Cost/Share
$0.87
Shares
57,225
Total Value
$49,785.75
Owned After
4,784,111
SEC Form 4
Other
Avg Cost/Share
$0.87
Shares
57,225
Total Value
$49,785.75
Owned After
4,784,111
SEC Form 4
Director
Avg Cost/Share
$0.89
Shares
38,043
Total Value
$33,858.27
Owned After
2,973,099
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| EVNIN LUKE | HOWL | Director | Dec 9, 2025 | Sell | $1.01 | 44,570 | $45,015.70 | 2,973,099 | |
| EVNIN LUKE | HOWL | Director | Dec 8, 2025 | Sell | $0.99 | 34,041 | $33,700.59 | 2,973,099 | |
| EVNIN LUKE | HOWL | Director | Dec 5, 2025 | Sell | $0.97 | 16,568 | $16,070.96 | 2,973,099 | |
| EVNIN LUKE | HOWL | Director | Dec 4, 2025 | Sell | $0.97 | 53,416 | $51,813.52 | 2,973,099 | |
| MPM BioVentures 2014, L.P. | HOWL | Other | Dec 4, 2025 | Sell | $0.97 | 83,230 | $80,733.10 | 4,784,111 | |
| GADICKE ANSBERT | HOWL | Other | Dec 4, 2025 | Sell | $0.97 | 83,230 | $80,733.10 | 4,784,111 | |
| EVNIN LUKE | HOWL | Director | Dec 3, 2025 | Sell | $0.87 | 36,726 | $31,951.62 | 2,973,099 | |
| MPM BioVentures 2014, L.P. | HOWL | Other | Dec 3, 2025 | Sell | $0.87 | 57,225 | $49,785.75 | 4,784,111 | |
| GADICKE ANSBERT | HOWL | Other | Dec 3, 2025 | Sell | $0.87 | 57,225 | $49,785.75 | 4,784,111 | |
| EVNIN LUKE | HOWL | Director | Dec 2, 2025 | Sell | $0.89 | 38,043 | $33,858.27 | 2,973,099 |
Compare HOWL vs Leading Stocks
See how HOWL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "HOWL Werewolf Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.